Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?
| Autor: | Filiz Özülker, Çağlayan Geredeli, Sevda Sağlampınar Karyağar, Serdar Arici, Oğuzhan Selvi, Savaş Karyağar, Osman Güven |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Receptor expression Urology Gallium Radioisotopes urologic and male genital diseases Lesion Prostate cancer chemistry.chemical_compound Antigen Positron Emission Tomography Computed Tomography medicine Enzalutamide Humans Radiology Nuclear Medicine and imaging Gallium Isotopes Aged PET-CT business.industry Prostatic Neoplasms General Medicine Middle Aged medicine.disease Prostate-specific antigen Docetaxel chemistry medicine.symptom business medicine.drug |
| Zdroj: | Nuclear medicine communications. 42(9) |
| ISSN: | 1473-5628 |
| Popis: | Objective In patients with metastatic castration-resistant prostate cancer (mCRPCa), enzalutamide is administered when docetaxel treatment fails. The purpose of the study was to evaluate the relationship between prostate-specific antigen (PSA) response and metabolic parameters obtained from 68Ga-PSMA PET/CT before treatment in this patient group. Methods From February 2018 to May 2020, 34 patients with mCRPCa were enrolled in this study. The association between PSA response (at least 50% decrease compared to the pretreatment value) and quantitative prostate-specific membrane antigen (PSMA) expression parameters such as SUVmax, SUVmean, PSMA-TV (PSMA receptor-expressing tumor volume) and TL-PSMA (total lesion PSMA receptor expression) were evaluated. Results Mean SUVmax, SUVmean, PSMA receptor-expressing tumor volume (PSMA-TV) and total lesion PSMA receptor expression (TL-PSMA) values were 33.66 ± 20.42; 8.82 ± 5.03; 319.85 ± 615.12 cm3; and 2894.76 ± 5195.13, respectively. In the posttreatment 12th week, 22 patients (64.7%) had PSA response, while 12 patients (35.3%) were nonresponders. In patients with PSA response, PSMA-TV values were significantly lower than nonresponders (78.37 ± 80.99 cm3 vs. 451.58 ± 734.61 cm3; P = 0.028). But there was no significant difference between responders and nonresponders in terms of age, ISUP grade, SUVmax, SUVmean, TL-PSMA, pretreatment PSA values, presence of local recurrence or metastases at any site. Conclusion PSMA-TV values on 68Ga-PSMA PET/CT imaging before starting enzalutamide treatment following docetaxel failure can predict PSA response in patients with mCRPCa. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|